Lv1
64 积分 2025-11-17 加入
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study
11天前
已完结
Lenacapavir treatment–emergent HIV-1 capsid resistance mutations are frequently associated with replication defects
11天前
已完结
Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxis
11天前
已关闭
Structural characterization of a human Fc fragment engineered for lack of effector functions
22天前
已完结
Two sides of the same coin: Protective versus pathogenic CD4 + resident memory T cells
1个月前
已完结
Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope
1个月前
已完结
CARD8 is an inflammasome sensor for HIV-1 protease activity
2个月前
已完结
Immune-mediated strategies to solving the HIV reservoir problem
2个月前
已完结
Assessment of the susceptibility of mutant HIV-1 to antiviral agents
3个月前
已完结
Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults
3个月前
已完结
皖公网安备34019202002308
